Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients

Type 2 Diabetes Clinical Trial

— INFINITI2019  

Official title:

Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients: The INFINITI Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04965935
• Other study ID #: 19-5342
• Status: Recruiting
• Phase: Phase 3
• Start date: July 15, 2021
• Est. completion date: June 15, 2024

Study information

• Verified date: May 2023
• Source: University Health Network, Toronto
• Contact: Vesta Lai, RN
• Phone: 416-340-4800
• Email: vesta.lai[@]uhn.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will be a randomized, double-blind, placebo-controlled clinical trial comparing the SGLT2 inhibitor dapagliflozin to placebo in 52 kidney transplant recipients (KTR) with or without pre-existing type 2 diabetes (T2D) or post-transplant diabetes mellitus (PTDM). The primary outcome of the trial is to determine if dapagliflozin is superior to placebo in reduction of blood pressure in KTR.

Description:

Kidney transplantation is the renal replacement therapy of choice for patients with end stage renal disease (ESRD). It has been well established that kidney transplantation improves patient survival and quality of life, and results in significant savings to the health care system. Despite the survival benefit conferred by transplantation, KTR still face a number of challenges, especially in patients with diabetes. First, KTR still have a higher risk of mortality than their age-matched counterparts without kidney disease. This mortality risk is even greater amongst KTR with diabetes. Furthermore, mortality from cardiovascular disease (CVD) continues to be an important problem after transplantation. Another major challenge faced by KTR is the continuing risk of developing graft failure over time. Unfortunately, in the subgroup of KTR with diabetes, the incidence of graft failure is 50% higher than the general kidney transplant recipient population, and recurrent diabetic kidney disease (DKD) occurs in almost half of allografts after transplantation. Current strategies in the management of graft dysfunction and chronic kidney disease (CKD) are focused on optimizing immunosuppression and control of hypertension and dyslipidemia. Accordingly, there is an important unmet need for cardio- and renoprotective strategies to address premature death and graft loss in the KTR population. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are glucose lowering agents that are effective in the treatment of T2D, resulting not only in improved glycemic control, but also weight loss, blood pressure and albuminuria reduction. Several clinical trials have shown significant benefits of SGLT2i on cardiovascular and renal outcomes. Given the glucose-dependent and independent effects of SGLT2i, as well as the accumulating evidence demonstrating cardiorenal protection in non-KTR, the use of these agents in KTR is attractive - especially since traditional renin-angiotensin-aldosterone system inhibitors are not effective. Moreover, the use of SGLT2i as a cardiorenal protective therapy may be of particular value in KTR given the high burden of comorbidities such as diabetes, CVD and hypertension, as well as the ongoing challenges of premature death and graft loss in this population. This study will be a randomized, double-blind, placebo-controlled clinical trial comparing the SGLT2 inhibitor dapagliflozin to placebo in 52 KTR with or without pre-existing T2D or PTDM. The primary outcome of the trial is to determine if dapagliflozin is superior to placebo in reduction of blood pressure in KTR. The secondary outcomes of this study include metabolic, vascular, renal and transplant-specific measures. These outcomes have been included to elucidate the potential mechanisms responsible for blood pressure lowering, and putative cardio- and renoprotective effects in KTR. Safety outcomes will also be assessed.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 52
• Est. completion date: June 15, 2024
• Est. primary completion date: June 15, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

1. Male or females >18 years old = 6months after kidney transplantation;

2. In patients with T2D or PTDM, HbA1c <12.0%;

3. eGFR =30 ml/min/1.73m^2 (as per the CKD-EPI equation);

4. BMI =45kg/m^2;

5. Blood pressure =160/90 and =90/60 at screening.

Exclusion Criteria:

1. Diagnosis of type 1 diabetes;

2. Presence of severe peripheral vascular disease (i.e. prior amputation, gangrene, non-healing ulcer or ischemic rest pain);

3. Presence of acute coronary syndrome, stroke or transient ischemic attack in the 3 months prior to screening;

4. Prior episode of graft pyelonephritis in the 1 month prior to screening;

5. Episode of acute graft rejection in the 3 months prior to screening;

6. Initiation of a new immunosuppressive agent or discontinuation of an immunosuppressive agent in the 1 month prior to screening;

7. Untreated urinary or genital tract infection;

8. Severe hypoglycemia within 3 months of screening, or hypoglycemia unawareness;

9. Pre-menopausal women who are nursing, pregnant, or of child-bearing potential and not practicing an acceptable method of birth control;

10. Participation in another trial with an investigational drug within 30 days of informed consent;

11. Alcohol or drug abuse within 3 months prior to informed consent that would interfere with trial participation;

12. Any ongoing clinical condition that would jeopardize subject safety or study compliance based on investigator judgement.

13. Patients currently using antipsychotic medications.

14. Use of SGLT2 inhibitors within 1 month of starting the study.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Kidney Transplant Recipients
• Post-transplant Diabetes Mellitus
• Type 2 Diabetes

Intervention

Drug:
• Dapagliflozin 10 MG Oral Tablet
Dapagliflozin will be administered in a dose of 10 mg/day for 12 weeks.
• Placebo Matching Dapagliflozin Oral Tablet
Placebo will be administered for 12 weeks.

Locations

Country	Name	City	State
Canada	Renal Physiology Laboratory	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Systolic blood pressure	SBP	Change from baseline systolic blood pressure (SBP) at 12 weeks of treatment
Secondary	Fasting plasma glucose	Fasting plasma glucose	Change from baseline fasting plasma glucose at 12 weeks of treatment
Secondary	HbA1c	HbA1c	Change from baseline HbA1c at 12 weeks of treatment
Secondary	Continuous home glucose monitoring	Continuous home glucose monitoring	Continuous glucose will be monitored for 14 days at 2 time intervals: 7 days prior to 7 days after drug administration (week -1 to1) and 7 days prior to 7 days after during drug discontinuation (week 11 to 13)
Secondary	Arterial stiffness	Measured using a Sphygmocor device	Change from baseline arterial stiffness at 12 weeks of treatment
Secondary	Systemic vascular resistance	Measured using non-invasive cardiac output monitor (NICOM)	Change from baseline systemic vascular resistance at 12 weeks of treatment
Secondary	Glomerular Filtration Rate	GFR	Change from baseline GFR (based on plasma iohexol clearance) at 12 weeks of treatment
Secondary	Estimated Glomerular Filtration Rate	eGFR	Change from baseline eGFR (based on CKD-EPI equation) at 12 weeks of treatment
Secondary	Proximal tubular natriuresis	Measured by fractional excretion of sodium and 24-hour urine collection	Change from baseline proximal tubular natriuresis at 12 weeks of treatment
Secondary	Albuminuria	Albuminuria	Change from baseline albuminuria at 12 weeks of treatment
Secondary	Urinary and plasma concentration of oxidative stress markers	Measured using ELISA	Change from baseline oxidative stress markers at 12 weeks of treatment
Secondary	Tubulointerstitial hypoxia	Measured using a renal ultrasound (photoacoustic ultrasonography)	Change from baseline tubulointerstitial hypoxia at 12 weeks of treatment
Secondary	Calcineurin inhibitor (CNI) Levels	CNI	Change from baseline CNI at 12 weeks of treatment
Secondary	Adverse Events (AEs)	AEs	Adverse events will be recorded from baseline throughout the study duration up to 13 weeks